Multiple Myeloma
Phase I
Accepting Patients
nct/study# NCT04093596 / ALLO-715-101
A Single-Arm, Open-Label, Phase 1 Study Of The Safety, Efficacy, And Cellular Kinetics/Pharmacodynamics Of ALLO-715 To Evaluate An Anti-BCMA Allogeneic CAR T Cell Therapy In Subjects With Relapsed/Refractory Multiple Myeloma
Learn More
Multiple Myeloma
Phase II
Accepting Patients
nct/study# NCT03601078 / BB2121-MM-002
A Phase 2, Multi-Cohort, Open-Label, Multicenter Study To Determine The Efficacy And Safety Of BB2121 In Subjects With Multiple Myeloma (Karmma-2)
Learn More
Multiple Myeloma
Phase III
Accepting Patients
nct/study# NCT03651128 / BB2121-MM-003
A Phase 3, Multicenter, Randomized, Open Label Study To Compare The Efficacy And Safety Of Bb2121 Versus Standard Triplet Regimens In Subjects With Relapsed And Refractory Multiple Myeloma
Learn More
Multiple Myeloma
Phase I
Accepting Patients
nct/study# NCT04196491 / BB-2121-MM-004
A Phase 1, Open-Label, Multicenter Study To Evaluate The Safety Of Bb2121 In Subjects With High Risk, Actively Diagnosed Multiple Myeloma (Karmma-4)
Learn More
Multiple Myeloma
Phase I/II
Accepting Patients
nct/study# NCT02773030 / CC-220-MM-001
A Phase 1b/2a Multicenter, Open-Label, Dose-Escalation Study To Determine The Maximum Tolerated Dose, Assess The Safety, Tolerability, Pharmacokinetics And Efficacy Of CC-220 As Monotherapy And In Combination With Other Treatments In Subjects With Multiple Myeloma
Learn More
Multiple Myeloma
Phase I
Accepting Patients
nct/study# NCT04142619 / UCARTS1A
Phase I, Open Label Dose-Escalation Study To Evaluate The Safety, Expansion, Persistence And Clinical Activity Of UCARTCS1A (Allogeneic Engineered T-Cells Expressing Anti-CS1 Chimeric Antigen Receptor), Administered In Patients With Relapsed/Refractory Multiple Myeloma
Learn More
